Justice makes arrests in $2.1B healthcare scheme

Thirty-five defendants have been charged by the Department of Justice in a Medicare fraud case worth more than $2.1 billion. The healthcare fraud case is one of the biggest ever charged.

The case involved fraudulent genetic testing across dozens of telemedicine companies and cancer genetic testing laboratories, charging CEOs, CFOs and others. The DOJ worked with HHS and FBI. CMS’ Center for Program Integrity (CMS/CPI) also announced administrative action against cancer genetic testing companies and medical professionals for $.17 billion in Medicare claims.

The fraud scheme involved illegal kickbacks and bribes by cancer genetic testing labs in exchange for Medicare beneficiary referrals from medical professionals working with fraudulent telemedicine companies. These tests were expensive and medically unnecessary.

In some cases, the tests were “worthless” to the beneficiaries’ doctors or weren’t performed at all, according to the DOJ. Allegedly, hundreds of thousands of elderly and disabled patients were lured into the network by the defendants.

“These defendants allegedly duped Medicare beneficiaries into signing up for unnecessary genetic tests, costing Medicare billions of dollars,” Assistant Attorney General Brian A. Benczkowski of the Justice Department’s Criminal Division said in a statement. “Together with our law enforcement partners, the Department will continue to protect the public fisc and prosecute those who steal our taxpayer dollars.”

The DOJ announced charges against defendants in Florida, Louisiana, Georgia, Texas and New Jersey.

“Unfortunately, audacious schemes such as those alleged in the indictments are pervasive and exploit the promise of new medical technologies such as genetic testing and telemedicine for financial gain, not patient care,” Deputy Inspector General for Investigations Gary L. Cantrell of HHS-OIG, said in a statement.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.